PATIENT SUPPORT PROGRAM - ENTYVIO PATHWAY
Entyvio Pathway is a nationwide support program developed by Takeda to help people get the most out of their ENTYVIO® treatment.
The program provides access to the following resources and services:
Home infusion support for intravenous (IV) induction doses, i.e. at weeks 0, 2, 6 for ulcerative colitis (UC), chronic pouchitis and Crohn’s disease (CD) ± week 10 for CD
In-home or virtual self-injection training with the ENTYVIO subcutaneous (SC) pre-filled pen
Home delivery of self-injection supplies
Travel resources
Questionnaires to assess ongoing persistence and self-injection confidence
Tailored educational content based on patient-reported confidence
ENTYVIO® is indicated for the treatment of adult patients with moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a TNFα antagonist.
ENTYVIO® is indicated for the treatment of adult patients with moderate to severe chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.
PBS Information: Authority Required. Refer to PBS for full details.
CLICK HERE TO REVIEW FULL APPROVED PRODUCT INFORMATION BEFORE PRESCRIBING.
ENTYVIO®, the ENTYVIO Logo® and the Entyvio Pathway Logo® are registered trademarks of Millennium Pharmaceuticals, Inc., a Takeda company.